Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections.
about
Effective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin BFrom Bench-Top to Bedside: A Prospective In Vitro Antibiotic Combination Testing (iACT) Service to Guide the Selection of Rationally Optimized Antimicrobial Combinations against Extensively Drug Resistant (XDR) Gram Negative Bacteria (GNB)Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.In vitro antibiotic synergy in extensively drug-resistant Acinetobacter baumannii: the effect of testing by time-kill, checkerboard, and Etest methods.Extensively drug-resistant Acinetobacter baumannii in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations.Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii.Carbapenemase-producing Enterobacteriaceae.High performance liquid chromatography-mass spectrometry assay for polymyxin B1 and B2 in human plasma.Analytical and functional determination of polymyxin B protein binding in serum.Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen designStructure-activity relationships for the binding of polymyxins with human α-1-acid glycoproteinPharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?Pharmacokinetics and renal disposition of polymyxin B in an animal model.In Vitro Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B.Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model.Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant Escherichia coli in Time-Kill Studies and in a Hollow-Fiber Infection Model.Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy.Development and validation of a liquid chromatography-mass spectrometry assay for polymyxin B in bacterial growth media.Surveillance and management of multidrug-resistant microorganisms.Polymyxins: wisdom does not always come with age.Polymyxin B versus colistin: an update.Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence.Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.Critical Need for Clarity in Polymyxin B DosingPharmacokinetics of polymyxin B in a patient with renal insufficiency: a case reportPharmacokinetics of intravenous polymyxin B in critically ill patients.Population pharmacokinetics of polymyxin B in acutely ill adult patients.Population Pharmacokinetics of Intravenous Polymyxin B from Clinical Samples.Population Pharmacokinetics of Polymyxin B.
P2860
Q28478261-31C7412B-EF49-4571-9BFF-853E2CF7CAB8Q28552767-716D82DC-B000-4133-B7E1-01BD0616ACB2Q34346283-467B61E9-30CD-41BA-A5E7-BF19E2CD7956Q34483679-F7C3EAE3-0800-49C2-825A-072A38E87E6BQ35041371-6C8F451E-6104-4354-B817-750EBDC744B0Q35385769-4760837A-20C0-4F07-8DC9-2E3EC3268A45Q35751615-8E0B5D0A-DEB7-4483-9F03-92EA2C659DCBQ36089663-99DA9B22-1982-4294-AF24-E448CDB01D94Q36158217-1FB5179A-404E-493D-8E24-2D3A95D39DCFQ36172505-4578A1EE-E449-4493-BDF8-D03FA010C4E2Q36252997-11F5576A-0AFC-430F-8031-1FB499150575Q36335694-E1C49F7F-181E-4017-917B-415CE974E83DQ36364194-85B9DFF5-AAB1-4B9F-AFA6-D6022F52B87FQ37203872-688D87B8-9C6E-48A7-ACFC-3F2E6C1CAA57Q37360650-A7F1E032-05F7-484C-B8D7-636A33F45440Q37538693-64CB0311-12F2-43EB-A0E7-D45A2AFF6B62Q37656243-DFA119D0-E8F6-402E-AEF5-1436D6B56BB8Q37669021-82DF94C8-50E9-4472-955E-B490F3FE2D14Q37912231-96DFB7DE-7589-4D87-B9C7-1E49BDF598F0Q38111213-E0BE8DC0-C09C-45C9-B18E-6A1DA6E97C12Q38613051-57D22C68-BEAD-4A15-9046-0C0046245AA9Q40111993-F61140C6-3FBB-4B8F-A4DE-9FA20C84E6AAQ42285293-D908CB8A-9662-4DC0-9C60-4F3E8859EBF4Q42358815-9F4F970A-68A1-4469-81A4-AE313784779DQ42757854-1B9A4023-3CB6-4229-AF1A-E10659C1C179Q44808038-34178318-3484-4984-A9A7-8DE157583F37Q47195590-29E70A92-2013-4DFD-9082-044B190E048AQ47195600-02010F70-A5A1-4AC3-8BB8-BBA0338208E1Q47313113-4B2C1C74-31B0-410E-AF76-7431F128529A
P2860
Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Pharmacokinetics of polymyxin ...... negative bacterial infections.
@en
Pharmacokinetics of polymyxin ...... negative bacterial infections.
@nl
type
label
Pharmacokinetics of polymyxin ...... negative bacterial infections.
@en
Pharmacokinetics of polymyxin ...... negative bacterial infections.
@nl
prefLabel
Pharmacokinetics of polymyxin ...... negative bacterial infections.
@en
Pharmacokinetics of polymyxin ...... negative bacterial infections.
@nl
P2093
P921
P1476
Pharmacokinetics of polymyxin ...... negative bacterial infections.
@en
P2093
Andrea L H Kwa
Asok Kurup
Jenny G H Low
JingGuo Hou
Randall A Prince
Tze-Peng Lim
Vincent H Tam
P304
P356
10.1016/J.DIAGMICROBIO.2007.08.008
P577
2007-10-04T00:00:00Z